No Data
No Data
Zhejiang Jingxin Pharmaceutical (002020.SZ): First buyback of 0.86 million company shares.
Gelonghui, January 12th丨Zhejiang Jingxin Pharmaceutical (002020.SZ) announced that on January 10, 2025, the company repurchased 860,000 shares through a special securities account for stock buybacks via centralized bidding, accounting for 0.10% of the company's total share capital. The highest Fill Price for the repurchased shares was 12.16 yuan/share, while the lowest Fill Price was 11.99 yuan/share, with a total transaction value of 10.3827 million yuan (excluding transaction fees).
Huafu Securities: The demand potential in the lipid-lowering drug Industry is enormous, and several Innovative Drugs are about to receive data catalysis.
Multiple cutting-edge targets have welcomed data catalysts, with strong certainty in drug viability, suggesting to focus on domestic companies that are targeting new Innovative Drugs for lipid reduction.
Express News | Zhejiang Jingxin Pharmaceutical plans to use 0.2 billion yuan to 0.4 billion yuan of its own funds to repurchase shares.
Express News | The Pacific Securities: The change in policies for generic drug formulations presents a good opportunity for the development of the Industry.
Express News | The National Healthcare Security Administration held a symposium on centralized volume-based procurement of pharmaceuticals.
Express News | Relevant departments, enterprises, and experts introduce information related to centralized procurement: the quality of Pharmaceutical products is strictly monitored, with comprehensive inspections of enterprises and random sampling of varieties.